SENS Research Foundation is a 501(c)(3) nonprofit that works to research, develop and promote comprehensive regenerative medicine solutions for the diseases of aging.
SRF supports research projects focused on a damage repair paradigm at universities and institutes around the world with the goal of curing such age-related diseases as heart disease, cancer, and Alzheimer’s disease.
SRF educates the public and trains researchers to support a growing regenerative medicine field through advocacy campaigns and educational programs. For more information, please visit sens.org.
No. Rejuvenation biotechnologies by definition would work by restoring healthy structure and function to the body.
Clearly, the degenerative aging process causes a great deal of suffering within the scope of the lives we live now, and clearly we are not alone in making this observation; otherwise the entire field of geriatric medicine would not exist.
Therefore, even when discussing longevity as an incidental effect of SENS-type treatments, it should go without saying that our priority, and the true triumph of rejuvenation biotech, will be that of increasing the human healthspan – i.e., the proportion of life spent feeling and functioning well, as opposed to the proportion spent struggling to endure pain, disease, dementia, and so on.